A phase 3 study is currently evaluating the efficacy and safety of disitimab vedotin for the treatment of locally advanced or metastatic BC with low HER2-expression (ClinicalTrials.gov identifier: NCT04400695). This evidence concerns the gene ERBB2 and breast cancer.